Levels of components of the urokinasetype plasminogen activator system are related to chronic obstructive pulmonary disease parenchymal destruction and airway remodelling

Journal of International Medical Research

Volumn 40, Issue 3, 2012, Pages 976-985

  Zhang, Y ^a   Xiao, Wei ^a   Jiang, Y ^a   Wang, H ^a   Xu, X ^a   Ma, D ^a   Chen, H ^a   Wang, X ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Airway remodelling; Chronic obstructive pulmonary disease; Emphysema; Urokinase type plasminogen activator system

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR;

ADULT; ARTICLE; CELL STRUCTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; EMPHYSEMA; ENZYME BLOOD LEVEL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ALVEOLUS CELL; LUNG FUNCTION; LUNG PARENCHYMA; MACROPHAGE; MALE; PROTEIN FUNCTION; RETROSPECTIVE STUDY; AIRWAY REMODELING; CASE CONTROL STUDY; COMPUTER ASSISTED TOMOGRAPHY; IMMUNOHISTOCHEMISTRY; LUNG FUNCTION TEST; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

AIRWAY REMODELING; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84863096830     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000316     Document Type: Article

References (44)

1. Lin HH, Murray M, Cohen T, et al: Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a timebased, multiple risk factor, modelling study. Lancet 2008; 372: 1473-1483.
2. Fang X, Wang X, Bai C: COPD in China: the burden and importance of proper management. Chest 2011; 139: 920-929.
3. Danø K, Andreasen PA, Grøndahl-Hansen J, et al: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
4. Irigoyen JP, Muñoz-Cánoves P, Montero L, et al: The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999; 56: 104-132.
5. Dear AE, Medcalf RL: The urokinase-typeplasminogen-activator receptor (CD87) is a pleiotropic molecule. Eur J Biochem 1998; 252: 185-193.
6. Vassalli JD, Sappino AP, Belin D: The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-1072.
7. Kucharewicz I, Kowal K, Buczko W, et al: The plasmin system in airway remodeling. Thromb Res 2003; 112: 1-7.
8. Mondino A, Blasi F: uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004; 25: 450-455.
9. Fuchs-Buder T, de Moerloose P, Ricou B, et al: Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 163-167.
10. Hattori N, Degen JL, Sisson TH, et al: Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000; 106: 1341-1350.
11. Oh CK, Ariue B, Alban RF, et al: PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochem Biophys Res Commun 2002; 294: 1155-1160.
12. Barton SJ, Koppelman GH, Vonk JM, et al: PLAUR polymorphisms are associated with asthma, PLAUR levels, and lung function decline. J Allergy Clin Immunol 2009; 123: 1391-1400.
13. Cho SH, Tam SW, Demissie-Sanders S, et al: Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma. J Immunol 2000; 165: 3154-3161.
14. Xiao W, Hsu YP, Ishizaka A, et al: Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest 2005; 128: 2316-2326.
15. Wang IM, Stepaniants S, Boie Y, et al: Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med 2008; 177: 402-411.
16. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1136.
17. Rabe KF, Hurd S, Anzueto A, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
18. Grydeland TB, Dirksen A, Coxson HO, et al: Quantitative computed tomography measures of emphysema and airway wall thickness are related to respiratory symptoms. Am J Respir Crit Care Med 2010; 181: 353-359.
19. Gevenois PA, de Maertelaer V, De Vuyst P, et al: Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 1995; 152: 653-657.
20. Cederqvist K, Sirén V, Petäjä J, et al: High concentrations of plasminogen activator inhibitor-1 in lungs of preterm infants with respiratory distress syndrome. Pediatrics 2006; 117: 1226-1234.
21. Malkusch W, Rehn B, Bruch J: Advantages of Sirius Red staining for quantitative morphometric collagen measurements in lungs. Exp Lung Res 1995; 21: 67-77.
22. Crisby M, Nordin-Fredriksson G, Shah PK, et al: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-933.
23. Nagase H: Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-160.
24. Okumura Y, Sato H, Seiki M, et al: Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator. FEBS Lett 1997; 402: 181-184.
25. Morris DG, Huang X, Kaminski N, et al: Loss of integrin i(v) β6-mediated TGF-β activation causes Mmp12-dependent emphysema. Nature 2003; 422: 169-173.
26. Imai K, Dalal SS, Chen ES, et al: Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med 2001; 163: 786-791.
27. Culpitt SV, Rogers DF, Traves SL, et al: Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. Respir Med 2005; 99: 703-710.
28. Vignola AM, Paganin F, Capieu L, et al: Airway remodelling assessed by sputum and highresolution computed tomography in asthma and COPD. Eur Respir J 2004; 24: 910-917.
29. Baraldo S, Bazzan E, Zanin ME, et al: Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. Chest 2007; 132: 1733-1740.
30. Vernooy JH, Lindeman JH, Jacobs JA, et al: Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004; 126: 1802-1810.
31. Han XD, Xiao W, Liu CX, et al: Effect of amiloride on the pathology of a rat model of chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi 2007; 30: 363-367 [in Chinese, English abstract].
32. Gyetko MR, Chen GH, McDonald RA, et al: Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J Clin Invest 1996; 97: 1818-1826.
33. Gyetko MR, Sud S, Chen GH, et al: Urokinasetype plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection. J Immunol 2002; 168: 801-809.
34. D'hulst AI, Maes T, Bracke KR, et al: Cigarette smoke-induced pulmonary emphysema in scidmice. Is the acquired immune system required? Respir Res 2005; 6: 147.
35. Simon RH, Gross TJ, Edwards JA, et al: Fibrin degradation by rat pulmonary alveolar epithelial cells. Am J Physiol 1992; 262: L482-L488.
36. Blasi F, Carmeliet P: uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-943.
37. 2 integrins in vivo. J Exp Med 1998; 188: 1029-1037.
38. Gyetko MR, Sud S, Sonstein J, et al: Antigendriven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA. J Immunol 2001; 167: 5539-5542.
39. Gyetko MR, Sud S, Kendall T, et al: Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol 2000; 165: 1513-1519.
40. Rijneveld AW, Levi M, Florquin S, et al: Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002; 168: 3507-3511.
41. Hogg JC, Chu F, Utokaparch S, et al: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
42. Finkelstein R, Fraser RS, Ghezzo H, et al: Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 1995; 152: 1666-1672.
43. Wasswa-Kintu S, Gan WQ, Man SF, et al: Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 2005; 60: 570-575.
44. Montuori N, Mattiello A, Mancini A, et al: Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma. Int J Cancer 2003; 105: 353-360.